In vitro anti-tuberculosis activity of azole drugs against Mycobacterium tuberculosis clinical isolates

B R IMPERIALE; A. A. CATALDI; MORCILLO NORA

REVISTA ARGENTINA DE MICROBIOLOGíA

ASOCIACION ARGENTINA MICROBIOLOGIA

Lugar: CABA; Año: 2017 vol. 49 p. 332 - 338

0325-7541

AbstractBackground: Latent tuberculosis has been associated with the persistence of dormantMycobacterium tuberculosis in the organism of infected individuals, who are reservoirs ofthe bacilli and the source for spreading the disease in the community. New active anti-TBdrugs exerting their metabolic action at different stages and on latent/dormant bacilli areurgently required to avoid endogenous reactivations and to be part of treatments of multiandextensively-drug resistant tuberculosis (M/XDR-TB). It was previously reported that azoledrugs are active against M. tuberculosis. For that reason, the aims of this study were to determinethe in vitro activity of azole drugs, imidazole (clotrimazole, CLO and econazole, ECO)and nitroimidazole (metronidazole, MZ and ipronidazole, IPZ), against a collection of MDR M.tuberculosis clinical isolates; and to analyze their potential use in both the LTB and the activeforms of M/XDR-TB treatments.Methods: A total of 55 MDR M. tuberculosis isolates and H37Rv were included. MZ and IPZactivity against M. tuberculosis isolates were tested using anaerobic culture conditions. Theactivity of ECO and CLO was measured by the minimal inhibitory concentration (MIC) using amicrodilution colorimetric method.Results: MZ and IPZ showed bacteriostatic activity against M. tuberculosis strains. MIC50 andMIC90 to ECO was 4.0 !g/ml, while MIC50 to CLO was 4.0 !g/ml and MIC90 was 8.0 !g/ml respectively.Conclusion: All azole compounds tested in the study showed inhibitory activity against MDR M.tuberculosis clinical isolates.© 2017 Asociacion Argentina de Microbiolog ´ ´ıa. Published by Elsevier Espana, S.L.U. This is an ?open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).